ArticleMycopathologia2025
Keep the Hospital Clean: Diagnostic Performance of Ten Different Molecular and Culture-Based Methods to Detect Candidozyma (Candida) auris.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Multicenter performance evaluation of the SimplexaJournal of clinical microbiology · 2026Article
- RefractoryASM case reports · 2026Article
- Biocide Response of Candida auris.Mycoses · 2026Review
- Candidozyma auris in The Netherlands: No Evidence of Nosocomial Transmission Supported by Effective Infection Control Policies.Mycopathologia · 2026Article
- Infection prevention and control ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
- Evaluation of a high-throughputMicrobiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCandidozyma auris (formerly Candida auris) is a globally emerging potentially multi-drug resistant human pathogenic yeast. To detect C. auris we aimed to compare different culture-, and molecular-based methods.
methodsRectal swabs routinely collected in clinical care were spiked with different concentrations of C. auris. Co-infection/colonization was mimicked by spiking part of these samples with other pathogenic Candida species. Spiked materials were cultured at 37 or 42 °C using CHROMagar Candida and CHROMagar Candida Plus plates. In parallel, samples were incubated in a dulcitol salt enrichment broth. Additionally, we compared seven in-house and commercial molecular tests on the direct material and from the broth one day after inoculation.
resultsCulture-based methods showed sensitivities up to 100% within 48 h of incubation, although sensitivity decreased as low as 44% at lower concentrations (≤ 50 CFU per inoculum), in the presence of an abundance of other species and at higher temperature (42 °C). Incubation at 42 °C made visual identification possible since other species with similar colony morphologies did not grow at this temperature. No added value of using the dulcitol salt enrichment broth was found. qPCR on direct materials was highly sensitive and specific (both up to 100%) but major differences between various molecular tests were observed.
conclusionWe showed that both culture-based and molecular methods are sensitive for diagnosing C. auris. The clinical setting (routine screening versus an outbreak), local prevalence and the load in those that carry or are infected by C. auris are important factors to consider when determining which diagnostic tests should be employed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.